Abstract: Objective  To observe the clinical efficacy of liraglutide in the treatment of overweight, and obese type 2 dabetes mellitus(T2DM) complicated with nephropathy. 
Methods  Seventy overweight and obese T2DM patients with glycated hemoglobin(HbA1c)(7%≤HbA1c≤11%) were selected and randomly divided into two groups: insulin combined with metformin and/or acarbose group(insulin group) and liraglutide combined with metformin and/or acarbose group(liraglutide group). Before and at 24 weeks after treatment, body weight(WT), waist circumference(WC), HbA1c, insulin resistance index(HOMA-IR), urinary albumin creatinine ratio(UACR), estimation glomerular filtration rate(eGFR), serum and urinary α1 microglobulin(α1-MG), serum and urinary β2 microglobulin(β2-MG), and other indicators were analyzed. 
Results  At the end of the study, 30 patients in the insulin group completed the study and 31 patients in the liraglutide group completed the study. Compared with those before treatment, HbA1c, HOMA-IR, UACR, eGFR, serum α1-MG, urinary α1-MG, blood β2-MG and urinary β2-MG in the insulin group were lower significantly after treatment, which showed significant difference(P＜0.01). After treatment, WT, WC, body mass index, HbA1c, HOMA-IR, UACR, EGFR, serum α1-MG, urinary α1-MG, blood β2-MG, urinary β2-MG decreased significantly in liraglutide group compared with those before treatment, with statistical significance(P＜0.01). After treatment, UACR, eGFR, serum α1-MG, urinary α1-MG and urinary β2-MG decreased more significantly in the liraglutide group than in the insulin group, with statistical significance(P＜0.05). 
Conclusion  In the treatment of overweight and obese T2DM patients with nephropathy, liraglutide can not only reduce blood glucose and weight, but also improve renal function and delay the progression of nephropathy, and this effect is independent of the effect of lowering blood glucose.

Key words: diabetic nephropathies, overweight, liraglutide